Psychedelic Stocks Psychedelics and the Military: An Unlikely Alliance By Dennis Mutua April 23, 2024 Despite decades of stigma and legal barriers, recent years have brought a profound shift in attitudes towards psychedelics. Driven by scientific inquiry and a growing recognition of their potential therapeutic benefits, the benefi...
Psychedelic Stocks Arizona’s Psilocybin Legislation By Dennis Mutua April 19, 2024 Psilocybin’s therapeutic renaissance Once relegated to the realm of recreational drug use, psilocybin is now at the forefront of a discussion on the potential therapeutic benefits of psychedelics. Arizona is the latest state to ...
Psychedelic Stocks Ketamine and the Controlled Substances Act By Dennis Mutua March 13, 2024 Many people struggling with treatment-resistant depression, which does not respond to at least two types of treatment, are finally experiencing relief with intravenous ketamine therapy. Hundreds of ketamine clinics have been poppi...
Psychedelic Stocks Oregon Ketamine Clinics: New Potential Restrictions on Corporate Practice of Medicine By Dennis Mutua February 27, 2024 Should private equity be involved in health care? If so, in what types of settings? And to what extent? These are baseline considerations around a broad concept referred to as “corporate practice of medicine” (“CPOM”) that...
Psychedelic Stocks The Dangers of Ketamine Revisited By Dennis Mutua January 11, 2024 As most people know by now, ketamine clinics are prevalent in the United States. These clinics offer ketamine as a treatment for a variety of disorders, including pain relief, behavioral health disorders, opiate addiction, and man...
Psychedelic Stocks California Bill Proposes Psychedelic Assisted Therapy Workgroup By Dennis Mutua January 05, 2024 California recently failed at least twice in passing sweeping statewide psychedelic decriminalization bills: a) SB-58, which Governor Gavin Newsom vetoed last year, and b) SB-519, which didn’t garner enough support in the assemb...
Psychedelic Stocks A Closer Look at the FDA Warnings on Compounded Ketamine By Dennis Mutua January 02, 2024 On February 16, 2022 and October 10, 2023, the FDA issued two warnings about the use of compounded ketamine. The first warning is entitled, “FDA alerts health care professionals of potential risks associated with compounded keta...
Psychedelic Stocks Oregon Psilocybin: State of the State (2023) By Dennis Mutua December 22, 2023 It’s hard to believe that we are wrapping up the first year of the Oregon Psilocybin Services (OPS) program. Final rules were released at this time last year, following a protracted, two-year development period. The application ...